Quick Answer
MoonLake Immunotherapeutics reported Cash and Equivalents of $334.52 million for fiscal year 2025.
MoonLake Immunotherapeutics Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $334.52M | +85.4% |
| 2024 | $180.43M | -60.0% |
| 2023 | $451.17M | +1042.0% |
| 2022 | $39.51M | +391.4% |
| 2021 | $8.04M | +501.7% |
| 2020 | $1.34M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $350.74M | -6.6% | +14.4% |
| June 30, 2025 | $306.68M | -10.5% | +12.9% |
| March 31, 2025 | $271.57M | -40.8% | +50.5% |
| December 31, 2024 | $180.43M | -60.0% | -52.0% |
| September 30, 2024 | $375.66M | +18.1% | +9.6% |
| June 30, 2024 | $342.79M | -31.7% | -25.2% |
| March 31, 2024 | $458.44M | +814.5% | +1.6% |
| December 31, 2023 | $451.17M | +1042.0% | +41.8% |
- MoonLake Immunotherapeutics showed an increase of +85.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, MoonLake Immunotherapeutics’s cash and equivalents has grown by 24940.1% (from $1.34 million to $334.52 million).
- The most recent figure is from MoonLake Immunotherapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: